117 related articles for article (PubMed ID: 1810439)
1. Effective immunotherapy with local low doses of interleukin-2.
Den Otter W; Maas RA; Koten JW; Dullens HF; Bernsen M; Klein WR; Rutten VP; Steerenberg PA; Balemans L; Ruitenberg EJ
In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
[TBL] [Abstract][Full Text] [Related]
2. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.
Maas RA; Dullens HF; De Jong WH; Den Otter W
Cancer Res; 1989 Dec; 49(24 Pt 1):7037-40. PubMed ID: 2582444
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
6. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor regression induced by low doses of interleukin-2.
Maas RA; Dullens HF; Den Otter W
In Vivo; 1991; 5(6):637-41. PubMed ID: 1810449
[TBL] [Abstract][Full Text] [Related]
8. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
9. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
13. [Interleukin-2 and LAK cells in the local immunotherapy of tumors of the head and neck: an experimental model].
Sacchi M; Johnson JT; Whiteside TL; Cortesina G
Acta Otorhinolaryngol Ital; 1989; 9(4):391-8. PubMed ID: 2618654
[TBL] [Abstract][Full Text] [Related]
14. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
16. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
Everse LA; Bernsen MR; Dullens HF; Den Otter W
J Exp Ther Oncol; 1996 Jul; 1(4):231-6. PubMed ID: 9414409
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
18. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma.
Claessen AM; Bloemena E; Bril H; Meijer CJ; Scheper RJ
Cancer Res; 1992 May; 52(9):2440-6. PubMed ID: 1568214
[TBL] [Abstract][Full Text] [Related]
19. Local low-dose IL-2 therapy.
Den Otter W; Balemans L; Battermann JJ; Bernsen MR; Cadee JA; Dobrowolski Z; Everse LA; Fiszer-Maliszewska L; Gavhumende R; De Groot JW; De Groot K; Hennink WE; Hill FW; Jurgenliemp-Schulz I; Klein WR; Koten JW; Maas RA; Steerenberg P; Stewart R; Zembala M
Hepatogastroenterology; 1999 May; 46 Suppl 1():1280-6. PubMed ID: 10429975
[TBL] [Abstract][Full Text] [Related]
20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
